Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Stat of the Week: ‘Other Services’ Drops 19% in Q3:17
Investors have flocked to the “Other Services” sector this year, as its ancillary nature keeps the companies that comprise it largely outside the purview of reimbursement regulations and other stroke-of-the-pen sectors. The 42 transactions announced in this sector in the third quarter represent a 19% decrease from the previous quarter, and a 32% decrease compared with the year-earlier quarter. Deal volume accounted for 22% of the 192 deals announced in the past 12 months. The “Other Services” category covers products and services related to human health care, but in an ancillary way, such as contract research organizations, ambulatory surgery centers, institutional and... Read More »
Deal of the Week: Melinta/The Medicines Co.’s Antibiotics
As part of a previously announced restructuring plan, The Medicines Company (NASDAQ: MDCO) is selling its infectious disease business unit in order to double-down on its promising drug candidate, inclisiran. The drug is currently in Phase 3 development, and completion is expected in the second half of 2019. That’s a long way away, and MDCO needs “sufficient cash and liquidity” to reach the goal line. That’s why, on November 29, the company announced an agreement to sell its infectious disease business unit, including three marketed antibiotics, Vabomere, Orbactiv® and Minocin IV. Melinta Therapeutics, Inc. (NASDAQ: MLNT), the buyer, will pay $540 million, as well as... Read More »Health Care M&A Weekly Deals, The Week Ending December 1, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Astellas Pharma, Inc. Mitobridge, Inc. $225 million eHealth Acquirer Target Price Trinisys MICA Health N/A Home Health Care & Hospice Acquirer Target Price Webster Capital Bristol Hospice N/A... Read More »Health Care M&A Weekly Deals, The Week Ending November 24, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Long-Term Care Acquirer Target Price CA Senior Living LLC 3 assisted living communities N/A Pharmaceuticals Acquirer Target Price Kwangdong Pharmaceutical Co., Ltd. License to bremelanotide... Read More »
Dermatology Practice Deals Up 46% in 2017
Acquisitions of dermatology practices are surging in 2017. Through mid-November, we’ve counted 37 transactions for these physician practices, up nearly 46% compared with all of 2016 (26 announced transactions), according to our Deal Search Online database. As we’ve noted before, private equity play a significant role in the increased deal count. Epiphany Dermatology, a portfolio company of CI Capital Partners, has been the busiest acquirer this year, with eight transactions concentrated in Arizona, New Mexico, Oklahoma and Texas. All had three or fewer physicians, and none of the deals disclosed prices. Two privately held companies have announced five transactions apiece in... Read More »
Stat of the Week: 0% Growth in Q3 Pharma Deals
“Sluggish” is the best word to describe deal activity in the Pharmaceutical sector this year. Mergers and acquisitions have dropped every quarter since the third quarter of 2016. In Q3:17, this dearth of deals may have finally bottomed out. Deal making stayed even with the previous quarter, but that total represented the nadir for deal volume in the previous 12 months. At 16 deals, Q3:17 transactions made up 17% of the 94 deals announced in the past 12 months. The total is 59% lower than in the same quarter in 2016. As we noted in last quarter’s edition, the global pharmaceutical companies are waiting to see the outcome of President Trump’s tax reform efforts. They are in no... Read More »
Physician Practice Deals Down 15% in Q3:17
Physician medical groups are still hot properties, of course. But the rate of consolidation within the industry accelerated rapidly in the past two years, and it was inevitable the pace would slacken at some point. The 28 acquisitions announced in the third quarter represent 19% of the 145 deals announced in the previous 12 months. Deal volume was down 10% compared with the previous quarter, and down 15% versus the same quarter a year earlier. Longer payment cycles associated with value-based reimbursement is just one reason many physician practices have joined larger groups or health systems. Electronic medical records, revenue cycle management and billing are all necessities for today’s... Read More »
Stat of the Week: Managed Care Deals Up 50% in Q3:17
Deal volume in this sector was low in 2016, and through the first half of 2017. Then deal activity doubled in the third quarter, if only to eight transactions. Third quarter deal volume represents a 40% share of the 20 deals announced in the previous 12 months, and a 167% increase over the same quarter in 2016. We don’t expect this sector to sustain even this level of activity, given recent events. Although the Republican party has control of Congress and the White House, efforts to repeal the Affordable Care Act were unsuccessful, even in a late September push. President Trump made clear his disappointment, and then issued a pair of executive orders on October 12 aimed directly at the... Read More »Health Care M&A Weekly Deals, The Week Ending November 17, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Janssen Biotech Inc. License to 6 bispecific antibodies $50 million ITUS Corporation License to CAR-T technology N/A Excision Biotherapeutics License to CRISPR gene editors N/A Monopar Therapeutics, Inc.... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
